BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
See today's BioWorld
Home
» Venture capital and other private biopharma financings in March 2020
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Venture capital and other private biopharma financings in March 2020
April 3, 2020
No Comments
Venture capital and other private financings of private biopharma companies, including: Abbisko, Advanced Biodesign, Affinia, Akouos, AM-Pharma, Amunix, Apexigen, Biosight, Castle Creek, Cinclus, Circle, Clarus, Design, Elevatebio, Eureka, Evonetix, Exuma, Harbour Biomed, Immunocore, Kallyope, Keros, Kymera, Lipidio, Nanjing Iaso, Numab, Nurix, Oncoone R&D, Onethree, Pliant, Polyprox, Primmune, Recode, Redpin, Regenacy, Sigilon, Silverback, Sutrovax, Svenska Vaccinfabriken Produktion, Syndivia, Tikomed, Xilio, Zucara.
BioWorld
Analysis and data insight